Webinars

The Oncology Center of Excellence (OCE) Project Optimus aims to refine dose optimisation in oncology by focusing on the safety and tolerability of a drug and not just efficacy. The goals for Project Optimus include the undertaking to “Develop strategies for dose finding and dose optimization that leverages nonclinical and clinical data in dose selection, […]

Early engagement with regulators is a key success factor in the delivery of early-phase clinical research. Proactive, early engagement via Regulatory Scientific Advice can mitigate risk with your CTA package further down the line. Dr Kirsty Wydenbach is Head of Regulatory Strategy at Weatherden, and also a member of our independent Drug Development Advisory Board. […]

We invited CEO of Simbec-Orion, Fabrice Chartier, and CEO of biotx.ai, Joern Klinger, to discuss how early utilisation of AI could help de-risk and accelerate clinical development, and where drug developers should start when considering adding AI to their clinical development strategy. Register to discover how the early inclusion of AI-enabled causal modelling can:

The discovery path for new oncology therapeutics is time-consuming and expensive, with figures of around 12 years and between $314M to $2.8B being shared (1).  The clinical line-of-sight essential for delivering a successful therapeutic programme is often considered late in the drug discovery process. This can contribute to the notoriously high attrition rates of drugs […]

Following our highly popular webinar, How to Take an Oncology Drug Into the Clinic, Senior Medical Director at Simbec-Orion, Dr Romillie Cruz talked with Professor Sarah Blagden, Professor of Medical Oncology, at the University of Oxford about some of the topics raised during the presentation.

Now available on demand Being first to market with an innovator drug remains the ultimate goal for all and most organisations are constantly reviewing timelines in order to achieve efficiencies through trial design, conduct and the reduction of down time between phases of their drug development. As a small biotech, how can you ensure that […]